Metabolic Syndromes: NASH & Diabetes

In 2008, Drs Scott Monte, Frank Bright, and Jerome Schentag noted that the mechanism of diabetes reversal by Bariatric Surgery, (specifically Roux-en-Y surgery, also called RYGB) was gastric bypass-mediated food stimulation of the distal intestine, the cause of a postprandial increase in GLP-1 and PYY.

These biomarkers were associated with decrease in insulin resistance and lack of hunger, in a manner similar to the surgery itself. We filed that patent in 2009, calling the phenomenon the “supply side” decrease of glucose as a means of lowering the body’s demand for insulin.

Subsequently, it became clear that the ileal delivery of glucose in the form of coated pills, could modify the course of insulin resistance, even after a single dose as low as 10gm.

Working with another inventor, Joseph Fayad, we together patented the action of ileal targeted oral glucose on Type 2 diabetes and subsequently on NASH. These subsequent patents were all filed between 2011 and 2013. Issued patents are listed, with links to download.

1. Monte SV, Bright FV, Schentag JJ. Patent:  Method and System to Provide Personalized Pharmaceutical Compositions and Dosages. US Provisional application 61/254,373 Filed October 23rd, 2009. Issued as US 8,367,418 B2 on February 5, 2013.

2. Schentag JJ, Fayad JM, Monte SV. Patent: Method and System to Provide Personalized Pharmaceutical Compositions and Dosages. Issued as US 8,999,721 B2 on April 7, 2015.

3. Schentag JJ, Fayad JM, Monte SV. Patent: Method and System to Provide Personalized Pharmaceutical Compositions and Dosages.
Issued as US 9,443,060 on September 13th, 2016.

4. Schentag JJ, Fayad JM. Patent:  Compositions, Methods of Treatment and Diagnostics for Treatment of Hepatic Steatosis alone, or in combination with a Hepatitis C virus infection. Issued as US 9,370,528 on June 21, 2016.

5. Fayad JM, Schentag JJ. Patent: Compositions, Methods of Treatment and Diagnostics for Treatment of Hepatic Steatosis alone and in Combination with a Hepatitis C virus infection. Issued as US 9,730,951 on August 15, 2017

6. Fayad JM, Schentag, J.J. Patent: Compositions, Methods of Treatment and Diagnostics for Treatment of Hepatic Steatosis Alone or in Combination with a Hepatitis C Virus Infection. Issued as US 10,245,277 B2 on April 2nd, 2019.